Vaniprevir: HCV NS3/4A protease inhibitor treatment of hepatitis C

E. Hammond, A. Lucas, M. Lucas, Elizabeth Phillips, Silvana Gaudieri

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{a22712b539d0425e8ce623b7316880c7,

title = "Vaniprevir: HCV NS3/4A protease inhibitor treatment of hepatitis C",

author = "E. Hammond and A. Lucas and M. Lucas and Elizabeth Phillips and Silvana Gaudieri",

year = "2010",

doi = "10.1358/dof.2010.035.010.1527293",

language = "English",

volume = "35",

pages = "803--813",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "10",

}

TY - JOUR

T1 - Vaniprevir: HCV NS3/4A protease inhibitor treatment of hepatitis C

AU - Hammond, E.

AU - Lucas, A.

AU - Lucas, M.

AU - Phillips, Elizabeth

AU - Gaudieri, Silvana

PY - 2010

Y1 - 2010

U2 - 10.1358/dof.2010.035.010.1527293

DO - 10.1358/dof.2010.035.010.1527293

M3 - Article

VL - 35

SP - 803

EP - 813

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 10

ER -